CDMO vs. LXRX, LRMR, TRDA, ADCT, TVTX, NGNE, ANNX, TBPH, CRBP, and ESPR
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Lexicon Pharmaceuticals (LXRX), Larimar Therapeutics (LRMR), Entrada Therapeutics (TRDA), ADC Therapeutics (ADCT), Travere Therapeutics (TVTX), Neurogene (NGNE), Annexon (ANNX), Theravance Biopharma (TBPH), Corbus Pharmaceuticals (CRBP), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices (NASDAQ:CDMO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
Lexicon Pharmaceuticals received 97 more outperform votes than Avid Bioservices when rated by MarketBeat users. However, 66.42% of users gave Avid Bioservices an outperform vote while only 64.66% of users gave Lexicon Pharmaceuticals an outperform vote.
97.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 2.4% of Avid Bioservices shares are owned by insiders. Comparatively, 6.8% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Avid Bioservices has a net margin of -13.10% compared to Lexicon Pharmaceuticals' net margin of -14,573.20%. Avid Bioservices' return on equity of -8.77% beat Lexicon Pharmaceuticals' return on equity.
Avid Bioservices has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Avid Bioservices has higher revenue and earnings than Lexicon Pharmaceuticals. Avid Bioservices is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avid Bioservices had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Avid Bioservices and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.15 beat Avid Bioservices' score of -0.36 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Avid Bioservices presently has a consensus price target of $14.25, suggesting a potential upside of 93.88%. Lexicon Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 216.46%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Avid Bioservices.
Summary
Avid Bioservices beats Lexicon Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
